Expert Panel Creates First Guidelines for IBD Treatment Adherence
Italian specialists develop consensus recommendations to identify and help IBD patients at risk of skipping medications.
Summary
Poor medication adherence is a major problem for inflammatory bowel disease (IBD) patients, leading to worse outcomes and higher healthcare costs. Italian gastroenterologists used a modified Delphi consensus process to create the first standardized guidelines for identifying patients at risk of non-adherence and improving treatment compliance. After reviewing existing literature, experts developed 13 statements about therapeutic adherence in IBD. Through two voting rounds, 12 statements achieved consensus with 80-100% agreement among specialists. The guidelines provide practical recommendations for clinicians to recognize high-risk patients and implement targeted strategies to improve medication adherence in IBD care.
Detailed Summary
Medication non-adherence represents a critical challenge in inflammatory bowel disease (IBD) management, significantly impacting patient quality of life while increasing hospitalizations and healthcare expenses. Despite its importance, standardized approaches for identifying and addressing adherence issues have been lacking.
Italian IBD specialists conducted a modified Delphi consensus study to establish evidence-based guidelines for therapeutic adherence. The multidisciplinary team included gastroenterologists, psychologists, and patient advocacy representatives from across Italy. They performed an extensive literature review and developed 13 consensus statements covering adherence definitions, risk factors, and patient identification strategies.
The consensus process involved two voting rounds using a 1-9 agreement scale, with statements requiring ≥7 for approval. All 13 statements initially achieved mean scores ≥7, and after plenary discussion, 12 statements reached final consensus with agreement ranging from 80% to 100% among participants.
The resulting guidelines provide clinicians with practical tools to identify IBD patients at higher risk of medication non-adherence and implement appropriate intervention strategies. This represents the first standardized, expert-consensus approach to addressing therapeutic adherence in IBD care, potentially improving treatment outcomes and reducing healthcare burden.
The guidelines emphasize the need for dedicated physicians to promptly recognize at-risk patient profiles and deploy targeted adherence-enhancing strategies, marking a significant step forward in personalized IBD management approaches.
Key Findings
- 12 expert consensus statements achieved 80-100% agreement for IBD adherence guidelines
- First standardized approach to identify patients at risk of medication non-adherence
- Multidisciplinary panel included gastroenterologists, psychologists, and patient advocates
- Guidelines provide practical tools for clinicians to implement targeted interventions
- Poor adherence leads to worse outcomes, more hospitalizations, and higher costs
Methodology
Modified Delphi consensus method with extensive literature review, 13 initial statements, two voting rounds using 1-9 agreement scale with ≥7 cutoff for approval, and final plenary session for consensus refinement.
Study Limitations
Summary based on abstract only as full text not available. Specific details of the 12 consensus statements and implementation strategies not provided in the abstract.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.